320 related articles for article (PubMed ID: 8658737)
1. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
2. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
3. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
4. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
5. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
6. Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared with azathioprine.
Dunn JF; Hatch J; Precht A; Hart M; Li S
Transplant Proc; 1996 Apr; 28(2):955-7. PubMed ID: 8623479
[No Abstract] [Full Text] [Related]
7. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
8. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
9. Antibody therapy in steroid-resistant rejection.
Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
[No Abstract] [Full Text] [Related]
10. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
11. Role of cyclosporine rescue therapy in steroid resistant rejections.
Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
[No Abstract] [Full Text] [Related]
12. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
[No Abstract] [Full Text] [Related]
13. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
van Son WJ; van den Berg AP; The TH; Tegzess AM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
[No Abstract] [Full Text] [Related]
14. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
15. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
[No Abstract] [Full Text] [Related]
16. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
17. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B
J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
[No Abstract] [Full Text] [Related]
19. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E; Bellakoul R; Berthoux F
Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
[No Abstract] [Full Text] [Related]
20. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
